Molecular Factors in Carcinoma Ex Pleomorphic Adenoma: Systematic Review and Meta-Analysis

Key, S; Chia, C; Hasan, Z; Sundaresan, P; Riffat, F; Dwivedi, RC

Author(s): Key, S; Chia, C; Hasan, Z; Sundaresan, P; Riffat, F; Dwivedi, RC;
Details: Publication Year 2024-03,Volume 134,Issue #3,Page 1042-1053
Journal Title: Laryngoscope
Publication Type: Review
Abstract: OBJECTIVE: Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor. Although multiple reviews have been published on salivary gland malignancies, it has been a decade since the last dedicated systematic review pertaining to CXPA alone was published. This study examines molecular factors in CXPA diagnosis. DATA SOURCES: MEDLINE, CINAHL, Embase, Scopus, Web of Science (BIOSIS), Cochrane CENTRAL, Health Collection (Informit), OpenDOAR, and GreyNet International. REVIEW METHODS: Systematic review and meta-analysis from inception to October 31, 2022 for all English language studies pertaining to "carcinoma ex pleomorphic adenoma." Predicted incidence of each biomarker was calculated with meta-analysis. Comparison against pleomorphic adenoma (PA) and salivary duct carcinoma (SDC) when reported within the same study are performed. Risk of bias performed with JBI tool for prevalence studies. RESULTS: Of 19151 unique studies undergoing abstract screening, 55 studies (n = 1322 patients) underwent data analysis. Biomarkers with >3 studies were p53, HER2, AR, EGFR, PLAG1, ERBB, ER, PR, HMGA2, p16, p63, a-SMA, RAS, PTEN, PDL1, BRAF, PIK3CA, and c-kit. Highest incidence was seen in AR, EGFR, p16, and p53. Significant differences were demonstrated compared with PA and SDC. There was high heterogeneity and overall high risk of bias within studies. CONCLUSION: Molecular factors are an area of interest in the diagnosis of CXPA. Our study results support examining CXPA as a discrete cohort in future targeted therapy trials. Laryngoscope, 134:1042-1053, 2024.
Publisher: Wiley
Keywords: Humans; *Adenoma, Pleomorphic/diagnosis; Tumor Suppressor Protein p53; Biomarkers, Tumor; *Salivary Gland Neoplasms/pathology; *Adenocarcinoma; ErbB Receptors; biomarkers; carcinoma ex pleomorphic adenoma; meta-analysis; molecular targeted therapy; pleomorphic adenoma; salivary gland cancer; salivary gland neoplasms
Department(s): Surgical Oncology
Publisher's Version: https://doi.org/10.1002/lary.30993
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-04-04 03:09:36

Last Modified: 2024-04-04 03:11:20